5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Lactic O
acidosis O
: O
See O
boxed O
warning O
. O

( O
5.1 O
) O
* O
There O
have O
been O
postmarketing O
reports O
of O
acute O
pancreatitis O
, O
including O
fatal O
and O
non-fatal O
hemorrhagic O
or O
necrotizing O
pancreatitis O
. O

If O
pancreatitis O
is O
suspected O
, O
promptly O
discontinue O
JANUMET O
. O

( O
5.2 O
) O
* O
Heart O
failure O
has O
been O
observed O
with O
two O
other O
members O
of O
the O
DPP-4 O
inhibitor O
class O
. O

Consider O
risks O
and O
benefits O
of O
JANUMET O
in O
patients O
who O
have O
known O
risk O
factors O
for O
heart O
failure O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
. O

( O
5.3 O
) O
* O
There O
have O
been O
postmarketing O
reports O
of O
acute O
renal O
failure O
, O
sometimes O
requiring O
dialysis O
. O

Before O
initiating O
JANUMET O
and O
at O
least O
annually O
thereafter O
, O
assess O
renal O
function O
. O

( O
5.4 O
) O
* O
Vitamin O
B12deficiency O
: O
Metformin O
may O
lower O
Vitamin O
B12levels O
. O

Measure O
hematologic O
parameters O
annually O
. O

( O
5.5 O
) O
* O
When O
used O
with O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
or O
with O
insulin O
, O
a O
lower O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
may O
be O
required O
to O
reduce O
the O
risk O
of O
hypoglycemia O
. O

( O
5.7 O
) O
* O
There O
have O
been O
postmarketing O
reports O
of O
serious O
allergic O
and O
hypersensitivity O
reactions O
in O
patients O
treated O
with O
sitagliptin O
( O
one O
of O
the O
components O
of O
JANUMET O
) O
, O
such O
as O
anaphylaxis O
, O
angioedema O
, O
and O
exfoliative O
skin O
conditions O
including O
Stevens-Johnson O
syndrome O
. O

In O
such O
cases O
, O
promptly O
stop O
JANUMET O
, O
assess O
for O
other O
potential O
causes O
, O
institute O
appropriate O
monitoring O
and O
treatment O
, O
and O
initiate O
alternative O
treatment O
for O
diabetes O
. O

( O
5.9 O
) O
* O
Severe O
and O
disabling O
arthralgia O
has O
been O
reported O
in O
patients O
taking O
DPP-4 O
inhibitors O
. O

Consider O
as O
a O
possible O
cause O
for O
severe O
joint O
pain O
and O
discontinue O
drug O
if O
appropriate O
. O

( O
5.10 O
) O
* O
There O
have O
been O
postmarketing O
reports O
of O
bullous O
pemphigoid O
requiring O
hospitalization O
in O
patients O
taking O
DPP-4 O
inhibitors O
. O

Tell O
patients O
to O
report O
development O
of O
blisters O
or O
erosions O
. O

If O
bullous O
pemphigoid O
is O
suspected O
, O
discontinue O
JANUMET O
. O

( O
5.11 O
) O
* O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular O
risk O
reduction O
with O
JANUMET O
or O
any O
other O
anti-diabetic O
drug O
. O

( O
5.12 O
) O
5.1 O
Lactic O
Acidosis O
Metformin O
hydrochloride O
There O
have O
been O
postmarketing O
cases O
of O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
cases O
. O

These O
cases O
had O
a O
subtle O
onset O
and O
were O
accompanied O
by O
nonspecific O
symptoms O
such O
as O
malaise B-NonOSE_AE
, O
myalgias B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
respiratory B-NonOSE_AE
distress I-NonOSE_AE
, O
or O
increased B-NonOSE_AE
somnolence I-NonOSE_AE
; O
however O
, O
hypothermia B-NonOSE_AE
, O
hypotension B-NonOSE_AE
and O
resistant O
bradyarrhythmias B-NonOSE_AE
have O
occurred O
with O
severe O
acidosis B-NonOSE_AE
. O

Metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
was O
characterized O
by O
elevated B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
( O
> O
5 O
mmol/Liter O
) O
, O
anion B-OSE_Labeled_AE
gap I-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
( O
without O
evidence O
of O
ketonuria B-NonOSE_AE
or O
ketonemia B-NonOSE_AE
) O
, O
and O
an O
increased B-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
pyruvate I-OSE_Labeled_AE
ratio I-OSE_Labeled_AE
; O
metformin O
plasma O
levels O
were O
generally O
> O
5 O
mcg/mL O
. O

Metformin O
decreases O
liver O
uptake O
of O
lactate O
increasing B-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
which O
may O
increase O
the O
risk O
of O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
, O
especially O
in O
patients O
at O
risk O
. O

If O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
is O
suspected O
, O
general O
supportive O
measures O
should O
be O
instituted O
promptly O
in O
a O
hospital O
setting O
, O
along O
with O
immediate O
discontinuation O
of O
JANUMET O
. O

In O
JANUMET-treated O
patients O
with O
a O
diagnosis O
or O
strong O
suspicion O
of O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
, O
prompt O
hemodialysis O
is O
recommended O
to O
correct O
the O
acidosis B-NonOSE_AE
and O
remove O
accumulated O
metformin O
( O
metformin O
hydrochloride O
is O
dialyzable O
, O
with O
a O
clearance O
of O
up O
to O
170 O
mL/min O
under O
good O
hemodynamic O
conditions O
) O
. O

Hemodialysis O
has O
often O
resulted O
in O
reversal O
of O
symptoms O
and O
recovery O
. O

Educate O
patients O
and O
their O
families O
about O
the O
symptoms O
of O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
and O
if O
these O
symptoms O
occur O
instruct O
them O
to O
discontinue O
JANUMET O
and O
report O
these O
symptoms O
to O
their O
health O
care O
provider O
. O

For O
each O
of O
the O
known O
and O
possible O
risk O
factors O
for O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
, O
recommendations O
to O
reduce O
the O
risk O
of O
and O
manage O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
are O
provided O
below O
: O
Renal O
Impairment O
The O
postmarketing O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
cases O
primarily O
occurred O
in O
patients O
with O
significant O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

The O
risk O
of O
metformin O
accumulation O
and O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
increases O
with O
the O
severity O
of O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
because O
metformin O
is O
substantially O
excreted O
by O
the O
kidney O
. O

Clinical O
recommendations O
based O
upon O
the O
patient O
's O
renal O
function O
include O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
: O
* O
Before O
initiating O
JANUMET O
, O
obtain O
an O
estimated O
glomerular O
filtration O
rate O
( O
eGFR O
) O
. O

* O
JANUMET O
is O
contraindicated O
in O
patients O
with O
an O
eGFR B-Not_AE_Candidate
below I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

* O
JANUMET O
is O
not O
recommended O
in O
patients O
with O
an O
eGFR B-Not_AE_Candidate
between I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
and I-Not_AE_Candidate
< I-Not_AE_Candidate
4 I-Not_AE_Candidate
5 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
because O
these O
patients O
require O
a O
lower O
dosage O
of O
sitagliptin O
than O
what O
is O
available O
in O
the O
fixed O
combination O
JANUMET O
product O
. O

* O
Obtain O
an O
eGFR O
at O
least O
annually O
in O
all O
patients O
taking O
JANUMET O
. O

In O
patients O
at O
increased O
risk O
for O
the O
development O
of O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
e.g. O
, O
the O
elderly O
) O
, O
renal O
function O
should O
be O
assessed O
more O
frequently O
. O

Drug O
Interactions O
The O
concomitant O
use O
of O
JANUMET O
with O
specific O
drugs O
may O
increase O
the O
risk O
of O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
: O
those O
that O
impair B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
, O
result O
in O
significant O
hemodynamic B-NonOSE_AE
change I-NonOSE_AE
, O
interfere B-NonOSE_AE
with I-NonOSE_AE
acid I-NonOSE_AE
- I-NonOSE_AE
base I-NonOSE_AE
balance I-NonOSE_AE
or O
increase O
metformin O
accumulation O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Therefore O
, O
consider O
more O
frequent O
monitoring O
of O
patients O
. O

Age O
65 O
or O
Greater O
The O
risk O
of O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
increases O
with O
the O
patient O
's O
age O
because O
elderly O
patients O
have O
a O
greater O
likelihood O
of O
having O
hepatic B-Not_AE_Candidate
, O
renal O
, O
or O
cardiac O
impairment I-Not_AE_Candidate
than O
younger O
patients O
. O

Assess O
renal O
function O
more O
frequently O
in O
elderly O
patients O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

Radiological O
Studies O
with O
Contrast O
Administration O
of O
intravascular O
iodinated O
contrast O
agents O
in O
metformin-treated O
patients O
has O
led O
to O
an O
acute O
decrease B-NonOSE_AE
in I-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
and O
the O
occurrence O
of O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
. O

Stop O
JANUMET O
at O
the O
time O
of O
, O
or O
prior O
to O
, O
an O
iodinated O
contrast O
imaging O
procedure O
in O
patients O
with O
an O
eGFR B-Not_AE_Candidate
between I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
and I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
; O
in O
patients O
with O
a O
history O
of O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
alcoholism O
, O
or O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
; O
or O
in O
patients O
who O
will O
be O
administered O
intra-arterial O
iodinated O
contrast O
. O

Re-evaluate O
eGFR O
48 O
hours O
after O
the O
imaging O
procedure O
, O
and O
restart O
JANUMET O
if O
renal O
function O
is O
stable O
. O

Surgery O
and O
Other O
Procedures O
Withholding O
of O
food O
and O
fluids O
during O
surgical O
or O
other O
procedures O
may O
increase O
the O
risk O
for O
volume B-NonOSE_AE
depletion I-NonOSE_AE
, O
hypotension B-NonOSE_AE
and O
renal B-NonOSE_AE
impairment I-NonOSE_AE
. O

JANUMET O
should O
be O
temporarily O
discontinued O
while O
patients O
have O
restricted O
food O
and O
fluid O
intake O
. O

Hypoxic O
States O
Several O
of O
the O
postmarketing O
cases O
of O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
occurred O
in O
the O
setting O
of O
acute B-Not_AE_Candidate
congestive I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
( O
particularly O
when O
accompanied O
by O
hypoperfusion B-Not_AE_Candidate
and O
hypoxemia B-Not_AE_Candidate
) O
. O

Cardiovascular B-Not_AE_Candidate
collapse I-Not_AE_Candidate
( O
shock B-Not_AE_Candidate
) O
, O
acute B-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
sepsis B-Not_AE_Candidate
, O
and O
other O
conditions O
associated O
with O
hypoxemia B-Not_AE_Candidate
have O
been O
associated O
with O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
and O
may O
also O
cause O
prerenal B-NonOSE_AE
azotemia I-NonOSE_AE
. O

When O
such O
events O
occur O
, O
discontinue O
JANUMET O
. O

Excessive O
Alcohol O
Intake O
Alcohol O
potentiates O
the O
effect O
of O
metformin O
on O
lactate O
metabolism O
and O
this O
may O
increase O
the O
risk O
of O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
. O

Warn O
patients O
against O
excessive O
alcohol O
intake O
while O
receiving O
JANUMET O
. O

Hepatic O
Impairment O
Patients O
with O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
have O
developed O
with O
cases O
of O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
. O

This O
may O
be O
due O
to O
impaired O
lactate O
clearance O
resulting O
in O
higher B-NonOSE_AE
lactate I-NonOSE_AE
blood I-NonOSE_AE
levels I-NonOSE_AE
. O

Therefore O
, O
avoid O
use O
of O
JANUMET O
in O
patients O
with O
clinical O
or O
laboratory O
evidence O
of O
hepatic B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

5.2 O
Pancreatitis O
There O
have O
been O
postmarketing O
reports O
of O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
and O
non-fatal O
hemorrhagic B-OSE_Labeled_AE
or O
necrotizing O
pancreatitis I-OSE_Labeled_AE
, O
in O
patients O
taking O
JANUMET O
. O

After O
initiation O
of O
JANUMET O
, O
patients O
should O
be O
observed O
carefully O
for O
signs O
and O
symptoms O
of O
pancreatitis B-NonOSE_AE
. O

If O
pancreatitis B-NonOSE_AE
is O
suspected O
, O
JANUMET O
should O
promptly O
be O
discontinued O
and O
appropriate O
management O
should O
be O
initiated O
. O

It O
is O
unknown O
whether O
patients O
with O
a O
history O
of O
pancreatitis B-Not_AE_Candidate
are O
at O
increased O
risk O
for O
the O
development O
of O
pancreatitis B-NonOSE_AE
while O
using O
JANUMET O
. O

5.3 O
Heart O
Failure O
An O
association O
between O
dipeptidyl O
peptidase-4 O
( O
DPP-4 O
) O
inhibitor O
treatment O
and O
heart B-NonOSE_AE
failure I-NonOSE_AE
has O
been O
observed O
in O
cardiovascular O
outcomes O
trials O
for O
two O
other O
members O
of O
the O
DPP-4 O
inhibitor O
class O
. O

These O
trials O
evaluated O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
and O
atherosclerotic B-Not_AE_Candidate
cardiovascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Consider O
the O
risks O
and O
benefits O
of O
JANUMET O
prior O
to O
initiating O
treatment O
in O
patients O
at O
risk O
for O
heart B-NonOSE_AE
failure I-NonOSE_AE
, O
such O
as O
those O
with O
a O
prior O
history O
of O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
and O
a O
history O
of O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
and O
observe O
these O
patients O
for O
signs O
and O
symptoms O
of O
heart B-NonOSE_AE
failure I-NonOSE_AE
during O
therapy O
. O

Advise O
patients O
of O
the O
characteristic O
symptoms O
of O
heart B-NonOSE_AE
failure I-NonOSE_AE
and O
to O
immediately O
report O
such O
symptoms O
. O

If O
heart B-NonOSE_AE
failure I-NonOSE_AE
develops O
, O
evaluate O
and O
manage O
according O
to O
current O
standards O
of O
care O
and O
consider O
discontinuation O
of O
JANUMET O
. O

5.4 O
Assessment O
of O
Renal O
Function O
Metformin O
and O
sitagliptin O
are O
known O
to O
be O
substantially O
excreted O
by O
the O
kidney O
. O

Metformin O
hydrochloride O
JANUMET O
is O
contraindicated O
in O
patients O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Sitagliptin O
There O
have O
been O
postmarketing O
reports O
of O
worsening B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
including O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
sometimes O
requiring O
dialysis O
. O

Before O
initiation O
of O
therapy O
with O
JANUMET O
and O
at O
least O
annually O
thereafter O
, O
renal O
function O
should O
be O
assessed O
. O

In O
patients O
in O
whom O
development O
of O
renal B-NonOSE_AE
dysfunction I-NonOSE_AE
is O
anticipated O
, O
particularly O
in O
elderly O
patients O
, O
renal O
function O
should O
be O
assessed O
more O
frequently O
and O
JANUMET O
discontinued O
if O
evidence O
of O
renal B-NonOSE_AE
impairment I-NonOSE_AE
is O
present O
. O

5.5 O
Vitamin O
B12Levels O
In O
controlled O
clinical O
trials O
of O
metformin O
of O
29 O
weeks O
duration O
, O
a O
decrease B-OSE_Labeled_AE
to I-OSE_Labeled_AE
subnormal I-OSE_Labeled_AE
levels O
of O
previously O
normal O
serum O
Vitamin I-OSE_Labeled_AE
B I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
without O
clinical O
manifestations O
, O
was O
observed O
in O
approximately O
7 O
% O
of O
patients O
. O

Such O
decrease O
, O
possibly O
due O
to O
interference B-NonOSE_AE
with I-NonOSE_AE
B I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
absorption I-NonOSE_AE
from O
the O
B12-intrinsic O
factor O
complex O
, O
is O
, O
however O
, O
very O
rarely O
associated O
with O
anemia B-NonOSE_AE
and O
appears O
to O
be O
rapidly O
reversible O
with O
discontinuation O
of O
metformin O
or O
Vitamin O
B12supplementation O
. O

Measurement O
of O
hematologic O
parameters O
on O
an O
annual O
basis O
is O
advised O
in O
patients O
on O
JANUMET O
and O
any O
apparent O
abnormalities O
should O
be O
appropriately O
investigated O
and O
managed O
. O

[ O
See O
Adverse O
Reactions O
( O
6.1 O
) O
. O
] O

Certain O
individuals O
( O
those O
with O
inadequate B-Not_AE_Candidate
Vitamin I-Not_AE_Candidate
B I-Not_AE_Candidate
1 I-Not_AE_Candidate
2 I-Not_AE_Candidate
or O
calcium O
intake O
or O
absorption I-Not_AE_Candidate
) O
appear O
to O
be O
predisposed O
to O
developing O
subnormal B-NonOSE_AE
Vitamin I-NonOSE_AE
B I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
levels I-NonOSE_AE
. O

In O
these O
patients O
, O
routine O
serum O
Vitamin O
B12measurements O
at O
two- O
to O
three-year O
intervals O
may O
be O
useful O
. O

5.6 O
Change O
in O
Clinical O
Status O
of O
Patients O
with O
Previously O
Controlled O
Type O
2 O
Diabetes O
A O
patient O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
previously O
well O
controlled O
on O
JANUMET O
who O
develops O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
or O
clinical O
illness O
( O
especially O
vague O
and O
poorly O
defined O
illness O
) O
should O
be O
evaluated O
promptly O
for O
evidence O
of O
ketoacidosis B-NonOSE_AE
or O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
. O

Evaluation O
should O
include O
serum O
electrolytes O
and O
ketones O
, O
blood O
glucose O
and O
, O
if O
indicated O
, O
blood O
pH O
, O
lactate O
, O
pyruvate O
, O
and O
metformin O
levels O
. O

If O
acidosis B-NonOSE_AE
of O
either O
form O
occurs O
, O
JANUMET O
must O
be O
stopped O
immediately O
and O
other O
appropriate O
corrective O
measures O
initiated O
. O

5.7 O
Use O
with O
Medications O
Known O
to O
Cause O
Hypoglycemia O
Sitagliptin O
When O
sitagliptin O
was O
used O
in O
combination O
with O
a O
sulfonylurea O
or O
with O
insulin O
, O
medications O
known O
to O
cause O
hypoglycemia B-NonOSE_AE
, O
the O
incidence O
of O
hypoglycemia B-NonOSE_AE
was O
increased O
over O
that O
of O
placebo O
used O
in O
combination O
with O
a O
sulfonylurea O
or O
with O
insulin O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Therefore O
, O
patients O
also O
receiving O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
or O
insulin O
may O
require O
a O
lower O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
to O
reduce O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7.4 O
) O
] O
. O

Metformin O
hydrochloride O
Hypoglycemia B-NonOSE_AE
does O
not O
occur O
in O
patients O
receiving O
metformin O
alone O
under O
usual O
circumstances O
of O
use O
, O
but O
could O
occur O
when O
caloric O
intake O
is O
deficient O
, O
when O
strenuous O
exercise O
is O
not O
compensated O
by O
caloric O
supplementation O
, O
or O
during O
concomitant O
use O
with O
other O
glucose-lowering O
agents O
( O
such O
as O
sulfonylureas O
and O
insulin O
) O
or O
ethanol O
. O

Elderly O
, O
debilitated B-Not_AE_Candidate
, O
or O
malnourished O
patients O
, O
and O
those O
with O
adrenal B-Not_AE_Candidate
or O
pituitary O
insufficiency I-Not_AE_Candidate
or O
alcohol B-Not_AE_Candidate
intoxication I-Not_AE_Candidate
are O
particularly O
susceptible O
to O
hypoglycemic B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
. O

Hypoglycemia B-NonOSE_AE
may O
be O
difficult O
to O
recognize O
in O
the O
elderly O
, O
and O
in O
people O
who O
are O
taking O
beta-adrenergic O
blocking O
drugs O
. O

5.8 O
Loss O
of O
Control O
of O
Blood O
Glucose O
When O
a O
patient O
stabilized O
on O
any O
diabetic O
regimen O
is O
exposed O
to O
stress O
such O
as O
fever B-Not_AE_Candidate
, O
trauma B-Not_AE_Candidate
, O
infection B-Not_AE_Candidate
, O
or O
surgery O
, O
a O
temporary O
loss B-NonOSE_AE
of I-NonOSE_AE
glycemic I-NonOSE_AE
control I-NonOSE_AE
may O
occur O
. O

At O
such O
times O
, O
it O
may O
be O
necessary O
to O
withhold O
JANUMET O
and O
temporarily O
administer O
insulin O
. O

JANUMET O
may O
be O
reinstituted O
after O
the O
acute O
episode O
is O
resolved O
. O

5.9 O
Hypersensitivity O
Reactions O
There O
have O
been O
postmarketing O
reports O
of O
serious O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
treated O
with O
sitagliptin O
, O
one O
of O
the O
components O
of O
JANUMET O
. O

These O
reactions O
include O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
including O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Onset O
of O
these O
reactions O
occurred O
within O
the O
first O
3 O
months O
after O
initiation O
of O
treatment O
with O
sitagliptin O
, O
with O
some O
reports O
occurring O
after O
the O
first O
dose O
. O

If O
a O
hypersensitivity B-NonOSE_AE
reaction I-NonOSE_AE
is O
suspected O
, O
discontinue O
JANUMET O
, O
assess O
for O
other O
potential O
causes O
for O
the O
event O
, O
and O
institute O
alternative O
treatment O
for O
diabetes B-Not_AE_Candidate
. O

[ O
See O
Adverse O
Reactions O
( O
6.2 O
) O
. O
] O

Angioedema B-NonOSE_AE
has O
also O
been O
reported O
with O
other O
DPP-4 O
inhibitors O
. O

Use O
caution O
in O
a O
patient O
with O
a O
history O
of O
angioedema B-Not_AE_Candidate
with O
another O
DPP-4 O
inhibitor O
because O
it O
is O
unknown O
whether O
such O
patients O
will O
be O
predisposed O
to O
angioedema B-NonOSE_AE
with O
JANUMET O
. O

5.10 O
Severe O
and O
Disabling O
Arthralgia O
There O
have O
been O
postmarketing O
reports O
of O
severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
in O
patients O
taking O
DPP-4 O
inhibitors O
. O

The O
time O
to O
onset O
of O
symptoms O
following O
initiation O
of O
drug O
therapy O
varied O
from O
one O
day O
to O
years O
. O

Patients O
experienced O
relief O
of O
symptoms O
upon O
discontinuation O
of O
the O
medication O
. O

A O
subset O
of O
patients O
experienced O
a O
recurrence O
of O
symptoms O
when O
restarting O
the O
same O
drug O
or O
a O
different O
DPP-4 O
inhibitor O
. O

Consider O
DPP-4 O
inhibitors O
as O
a O
possible O
cause O
for O
severe O
joint B-NonOSE_AE
pain I-NonOSE_AE
and O
discontinue O
drug O
if O
appropriate O
. O

5.11 O
Bullous O
Pemphigoid O
Postmarketing O
cases O
of O
bullous B-OSE_Labeled_AE
pemphigoid I-OSE_Labeled_AE
requiring O
hospitalization O
have O
been O
reported O
with O
DPP-4 O
inhibitor O
use O
. O

In O
reported O
cases O
, O
patients O
typically O
recovered O
with O
topical O
or O
systemic O
immunosuppressive B-NonOSE_AE
treatment I-NonOSE_AE
and O
discontinuation O
of O
the O
DPP-4 O
inhibitor O
. O

Tell O
patients O
to O
report O
development O
of O
blisters B-NonOSE_AE
or O
erosions B-NonOSE_AE
while O
receiving O
JANUMET O
. O

If O
bullous B-NonOSE_AE
pemphigoid I-NonOSE_AE
is O
suspected O
, O
JANUMET O
should O
be O
discontinued O
and O
referral O
to O
a O
dermatologist O
should O
be O
considered O
for O
diagnosis O
and O
appropriate O
treatment O
. O

5.12 O
Macrovascular O
Outcomes O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular B-NonOSE_AE
risk O
reduction O
with O
JANUMET O
or O
any O
other O
anti-diabetic O
drug O
. O

